Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has a collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant; and has partnership with Vall d'Hebron Institute of Oncology to establish first guardant-based liquid biopsy testing service in Europe. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Date	Fund	Action	%
2023/03/08	ARKG	Buy	0.0561
2023/03/02	ARKG	Buy	0.0111
2023/02/27	ARKG	Buy	0.0417
2023/02/24	ARKG	Buy	0.0201
2022/07/29	ARKG	Buy	0.0883
2022/07/28	ARKG	Buy	0.0403
2022/07/27	ARKG	Buy	0.1194
2022/07/26	ARKG	Buy	0.5883
2022/07/25	ARKG	Buy	0.1362
2021/06/14	ARKG	Sell	0.0011
2021/06/11	ARKG	Sell	0.0189
2021/06/10	ARKG	Sell	0.1462
2021/06/09	ARKG	Sell	0.0047
2021/06/03	ARKG	Sell	0.0178
2021/06/02	ARKG	Sell	0.013
2021/06/01	ARKG	Sell	0.0327
2021/05/26	ARKG	Sell	0.0166
2021/05/25	ARKG	Sell	0.0402
2021/05/24	ARKG	Sell	0.2352
2021/05/20	ARKG	Sell	0.2739